11th May 2015 10:06
11 May 2015
Silence Therapeutics plc
Notice of AGM and posting of annual report and accounts
Silence Therapeutics plc, AIM: SLN, ("Silence" or "the Company"), a leader in the development and delivery of novel RNA therapeutics will be holding its AGM at 10am on Monday, 1 June 2015 at the offices of Silence Therapeutics, 1 Lyric Square, London, W6 0NB. Notice of the AGM can also be found on the website in the Investor Relations section.
The Company has posted to shareholders its annual report and accounts for the year ended 31 December 2014. The annual report can also be found online at:
http://silence-therapeutics.com/investors-media/investor-relations/#ResultsReportsPresentations
Enquiries:
Silence Therapeutics plc | +44 (0)20 3700 9711 |
Timothy Freeborn, Finance Director and Company Secretary | |
Rozi Morris, Communications Manager | |
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) | +44 (0)20 7523 8350 |
Dr Julian Feneley/Cara Griffiths/Henry Fitzgerald-O'Connor | |
Peel Hunt LLP (Joint Broker) | +44 (0)20 7418 8900 |
James Steel/ Oliver Jackson |
About Silence Therapeutics (www.silence-therapeutics.com)
Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need. Silence's technology is currently in the clinic in a Phase 2a pancreatic cancer trial.
Related Shares:
SLN.L